CN116236416A - 一种纳米负载的透明质酸钠及其制备方法和应用 - Google Patents
一种纳米负载的透明质酸钠及其制备方法和应用 Download PDFInfo
- Publication number
- CN116236416A CN116236416A CN202310191966.7A CN202310191966A CN116236416A CN 116236416 A CN116236416 A CN 116236416A CN 202310191966 A CN202310191966 A CN 202310191966A CN 116236416 A CN116236416 A CN 116236416A
- Authority
- CN
- China
- Prior art keywords
- sodium hyaluronate
- nano
- selenium
- solution
- mass concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920002385 Sodium hyaluronate Polymers 0.000 title claims abstract description 37
- 229940010747 sodium hyaluronate Drugs 0.000 title claims abstract description 37
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims description 10
- 239000011669 selenium Substances 0.000 claims abstract description 32
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 31
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 claims abstract description 30
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 claims abstract description 15
- 230000003266 anti-allergic effect Effects 0.000 claims abstract description 12
- 239000002537 cosmetic Substances 0.000 claims abstract description 5
- 239000002077 nanosphere Substances 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 20
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 18
- 238000009210 therapy by ultrasound Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 239000000084 colloidal system Substances 0.000 claims description 6
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 claims description 6
- 241001018563 Nekemias grossedentata Species 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 5
- -1 selenium ions Chemical class 0.000 claims description 5
- 244000269722 Thea sinensis Species 0.000 claims description 4
- 239000003638 chemical reducing agent Substances 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 238000003760 magnetic stirring Methods 0.000 claims description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- 235000021388 linseed oil Nutrition 0.000 claims description 2
- 239000000944 linseed oil Substances 0.000 claims description 2
- 238000001132 ultrasonic dispersion Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 2
- 241000252212 Danio rerio Species 0.000 abstract description 9
- 102000001400 Tryptase Human genes 0.000 abstract description 7
- 108060005989 Tryptase Proteins 0.000 abstract description 7
- 210000002257 embryonic structure Anatomy 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 239000002114 nanocomposite Substances 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 5
- 238000002834 transmittance Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- DEOKFPFLXFNAON-UHFFFAOYSA-N N-α-Benzoyl-DL-arginine 4-nitroanilide hydrochloride Chemical compound Cl.C=1C=C([N+]([O-])=O)C=CC=1NC(=O)C(CCCN=C(N)N)NC(=O)C1=CC=CC=C1 DEOKFPFLXFNAON-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
- A61K8/025—Explicitly spheroidal or spherical shape
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种纳米负载的透明质酸钠，其为三层纳米球结构，包括最外层的透明质酸钠，中间层的纳米硒以及内层的二氢杨梅素，纳米硒以二氢杨梅素为模板结合，再成为透明质酸钠的载体。本发明制备得到三层纳米球结构的透明质酸钠，该纳米复合物在斑马鱼水平上，可以有效降低斑马鱼胚胎中类胰蛋白酶的表达水平，具有很好的抗过敏作用，可作为原料应用于抗过敏化妆品。
Description
技术领域
本发明属于化妆品领域，具体涉及一种纳米负载的透明质酸钠及其制备方法和应用。
背景技术
近年来，倍受敏感肌困扰的人群越来越多，对抗过敏的需求也越来越大。敏感肌的成因复杂，其形成机制尚不明晰。目前研究中涉及的成因有皮肤屏障功能受损、表皮存在炎症状态、皮肤感受神经系统异常，而这些成因往往相互促进累及，导致敏感肌肤问题陷入不良循环，不易转变为正常皮肤。
根据目前研究中涉及到的敏感肌成因，抗过敏也主要从保湿修复抗炎等方面进行开发。
硒是生物体必需的微量元素之一，在生命活动中发挥着至关重要的作用。研究证实，硒是生物体中谷胱甘肽过氧化物酶、磷脂氢谷胱甘肽过氧化物酶活性中心的关键组成元素。此外硒还具有清除自由基、抗衰老、保护肝脏、免疫调节、抗肿瘤等多方面活性。但硒的有效剂量和毒性剂量之间范围狭窄，超过临界浓度则毒性很强，尽管纳米技术的使用降低了硒的毒性，提高了其利用度，但其稳定性问题仍存在，容易聚沉且容易氧化，导致其失效甚至毒性增加。
透明质酸钠是一种葡聚糖醛酸，广泛存在于胎盘、羊水、晶状体、关节软骨、皮肤真皮层等组织，是皮肤屏障修复的重要成分之一，在化妆品中最重要的作用是保湿修复，但很少单独使用，一般与其他功效性成分配伍使用。透明质酸钠具有大分子多糖结构，可作为载体，将具有活性的纳米硒负载于透明质酸钠上，既能很好地分散纳米硒分子间的间距，防止其因分子碰撞从而导致聚沉的问题，同时透明质酸钠对纳米硒分子表面进行包裹，从而防止其被钝化成无活性的单质硒而失效和毒性增强。
发明内容
本发明提出了一种纳米负载的透明质酸钠，其是将以藤茶提取物二氢杨梅素(DMY)为模板的纳米硒(nano-Se)负载到透明质酸钠(HA)上，制备得到三层纳米球结构的透明质酸钠，该纳米复合物更稳定，抗过敏功效更出色，在斑马鱼水平上，可以有效降低斑马鱼胚胎中类胰蛋白酶的表达水平，具有很好的抗过敏作用，可作为原料应用于抗过敏化妆品。
本发明上述目的通过以下技术方案予以实现：
一种纳米负载的透明质酸钠，其为三层纳米球结构，包括最外层的透明质酸钠，中间层的纳米硒以及内层的二氢杨梅素，纳米硒以二氢杨梅素为模板结合，再成为透明质酸钠的载体。
本发明的一种纳米负载的透明质酸钠的制备方法，包括以下步骤：
e.称取藤茶提取物，加入液体脂质和表面活性剂，超声至溶解；
f.往上述体系中加入蒸馏水，超声至溶解，得到以藤茶提取物的模板溶液；
g.取一定量模板溶液，加入含硒离子的溶液，混合均匀后，在超声分散条件下，逐滴滴加还原剂。滴加完毕后，超声30min，得到以藤茶提取物为模板的纳米硒，呈红色透明胶体状。
h.将上述制备得到的红色纳米硒胶体，在磁力搅拌下，逐滴加入等体积的透明质酸钠溶液，滴加完毕后，室温搅拌30min，得到纳米负载的透明质酸钠水溶液。
所述藤茶提取物主要为二氢杨梅素，质量浓度为0.02％；液体脂质主要为亚麻籽油、辛癸酸甘油酯等，质量浓度为0.4％；表面活性剂主要为吐温80，质量浓度为4％；含硒离子溶液主要为二氧化硒，质量浓度为1.75％；还原剂为抗坏血酸，质量浓度为5％；透明质酸钠溶液质量浓度为0.25％。
附图说明
图1为纳米负载的透明质酸钠的示意图；
图2-4为制备得到的纳米负载的透明质酸钠在不同倍数下的透射电镜图；
图5为制备得到的纳米负载的透明质酸钠的稳定性评价结果；
图6为制备得到的纳米负载的透明质酸钠的抗过敏功效结果。
具体实施方式
为让本领域的技术人员更加清晰直观的了解本发明，下面将结合附图，对本发明作进一步的说明。
实施例1纳米负载的透明质酸钠的制备
称取10mg二氢杨梅素，加入200uL辛/癸酸甘油三脂和2mL吐温80，超声至固体完全溶解后，加入45mL去离子水，超声搅拌均匀，得到二氢杨梅素模板溶液，备用。
往二氢杨梅素模板溶液中加入2mL质量浓度为1.75％的二氧化硒溶液，混合均匀，在超声下逐滴滴加3mL质量浓度为5％的抗坏血酸溶液，滴加完毕后，超声30min，得到纳米硒-二氢杨梅素纳米复合物，体系呈红色纳米胶体。
上述制备得到的红色纳米胶体在磁力搅拌下，逐滴往里滴加等体积的质量浓度为0.25％的透明质酸溶液，滴加完毕后，搅拌30min，得到纳米硒负载透明质酸钠体系。
在透射电镜下观察，如图2-4所示，制备得到的样品呈三层结构，从里到外分别是二氢杨梅素、纳米硒和透明质酸钠，粒径大约在200nm。
实施例2样品的稳定性评价
将透明质酸溶液、纳米硒和二氢杨梅素直接混合，得到一个混合物样品，作为参照。
以去离子水为空白对照，在紫外分光光度仪上分别对实施例1制备的样品和混合物样品进行全波长扫描，记录最大吸光度，根据A＝-LgT计算样品的透光率。
其中A为吸光度，T为透光率，透光率越大，样品越稳定。
测试结果如图5所示，实施例1制备得到的样品吸光度值为2.904，计算得透光率为0.12％，混合物的吸光度值为3.496，计算得透光率为0.03％。
从该结果可以看出，制备该三层结构的样品，比直接混合得到的样品体系更为稳定。
实施例3样品的抗过敏功效评价
挑选发育正常3dpf的斑马鱼置于96孔板中，每孔5条，模型对照组加入200μLCompound 48/80，测试组加入200μL受试样品溶液，溶剂对照组加入200μL蒸馏水，每个实验组设置3个复孔，于28℃孵育。
孵育后，每孔取100μL溶液置于0.5mL EP中，同时加入BAPNA，置于38℃孵育。
使用酶标仪检测各实验组的吸光值。Tryptase表达水平公式如下：
采用SPSS 19.0软件统计处理数据，实验数据均用
数据表示，用单因素方差分析。各浓度组与空白对照组两两比较：*P<0.05，**P<0.01，***P<0.005。
测试结果如图6所示，实施例1制备的样品和混合物均能有效抑制类胰蛋白酶的表达，具有抗过敏作用，其中实施例1制备的样品对斑马鱼Tryptase的相对表达水平为55.60±4.29％，混合物样品对斑马鱼Tryptase的相对表达水平为77.00±1.53％，低于模型对照组的斑马鱼Tryptase的相对表达水平(100.00±2.31％)，表示两个样品均具有抗过敏作用，且实施例1制备的样品效果优于混合物样品。
上述对实施例的描述是为便于该技术领域的普通技术人员能理解和应用本发明。熟悉本领域技术的人员显然可以容易地对这些实施例做出各种修改，并把在此说明的一般原理应用到其他实施例中而不必经过创造性的劳动。因此，本发明不限于这里的实施例，本领域技术人员根据本发明的揭示，对于本发明做出的改进和修改都应该在本发明的保护范围之内。
Claims (9)
1.一种纳米负载的透明质酸钠，其特征在于，其为三层纳米球结构，包括最外层的透明质酸钠，中间层的纳米硒以及内层的二氢杨梅素，纳米硒以二氢杨梅素为模板结合，再成为透明质酸钠的载体。
2.如权利要求1所述的一种纳米负载的透明质酸钠的制备方法，其特征在于，包括以下步骤：
a.称取藤茶提取物，加入液体脂质和表面活性剂，超声至溶解；
b.往上述体系中加入蒸馏水，超声至溶解，得到以藤茶提取物的模板溶液；
c.取一定量模板溶液，加入含硒离子的溶液，混合均匀后，在超声分散条件下，逐滴滴加还原剂；滴加完毕后，超声30min，得到以藤茶提取物为模板的纳米硒，
呈红色透明胶体状；
d.将上述制备得到的红色纳米硒胶体，在磁力搅拌下，逐滴加入等体积的透明质酸钠溶液，滴加完毕后，室温搅拌30min，得到纳米负载的透明质酸钠水溶液。
3.如权利要求2所述的制备方法，其特征在于，所述藤茶提取物主要为二氢杨梅素，质量浓度为0.02％。
4.如权利要求2所述的制备方法，其特征在于，所述液体脂质选自亚麻籽油、辛癸酸甘油酯，质量浓度为0.4％。
5.如权利要求2所述的制备方法，其特征在于，表面活性剂主要为吐温80，质量浓度为4％。
6.如权利要求2所述的制备方法，其特征在于，含硒离子溶液主要为二氧化硒，质量浓度为1.75％。
7.如权利要求2所述的制备方法，其特征在于，还原剂为抗坏血酸，质量浓度为5％。
8.如权利要求2所述的制备方法，其特征在于，透明质酸钠溶液质量浓度为0.25％。
9.如权利要求1所述的一种纳米负载的透明质酸钠在抗过敏化妆品中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310191966.7A CN116236416A (zh) | 2023-02-28 | 2023-02-28 | 一种纳米负载的透明质酸钠及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310191966.7A CN116236416A (zh) | 2023-02-28 | 2023-02-28 | 一种纳米负载的透明质酸钠及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116236416A true CN116236416A (zh) | 2023-06-09 |
Family
ID=86623849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310191966.7A Pending CN116236416A (zh) | 2023-02-28 | 2023-02-28 | 一种纳米负载的透明质酸钠及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116236416A (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102921015A (zh) * | 2012-10-24 | 2013-02-13 | 江苏大学 | 透明质酸纳米硒及其制备方法和用途 |
| CN111329876A (zh) * | 2020-03-25 | 2020-06-26 | 广东暨创硒源纳米研究院有限公司 | 纳米硒及其修饰物在制备抗过敏药物或抗过敏制剂中的应用 |
| CN111870562A (zh) * | 2020-08-14 | 2020-11-03 | 酉西(龙岩)生物科技有限责任公司 | 一种包含纳米硒的面膜、制备方法及应用方法 |
| CN112451514A (zh) * | 2020-11-26 | 2021-03-09 | 江西农业大学 | 二氢杨梅素纳米硒及其制备方法和应用 |
-
2023
- 2023-02-28 CN CN202310191966.7A patent/CN116236416A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102921015A (zh) * | 2012-10-24 | 2013-02-13 | 江苏大学 | 透明质酸纳米硒及其制备方法和用途 |
| CN111329876A (zh) * | 2020-03-25 | 2020-06-26 | 广东暨创硒源纳米研究院有限公司 | 纳米硒及其修饰物在制备抗过敏药物或抗过敏制剂中的应用 |
| CN111870562A (zh) * | 2020-08-14 | 2020-11-03 | 酉西(龙岩)生物科技有限责任公司 | 一种包含纳米硒的面膜、制备方法及应用方法 |
| CN112451514A (zh) * | 2020-11-26 | 2021-03-09 | 江西农业大学 | 二氢杨梅素纳米硒及其制备方法和应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Smijs et al. | Titanium dioxide and zinc oxide nanoparticles in sunscreens: focus on their safety and effectiveness | |
| Karakoti et al. | Direct synthesis of nanoceria in aqueous polyhydroxyl solutions | |
| Wang et al. | Therapeutic nanoparticles from grape seed for modulating oxidative stress | |
| KR101333209B1 (ko) | 파이토케미컬로 표면처리된 금나노입자를 유효성분으로 함유하는 피부노화방지용 화장료 조성물 | |
| CN107397714A (zh) | 具有抗蓝光污染和淡化细纹功效的精华乳及其制备与应用 | |
| CN108324606B (zh) | 一种火龙果茎提取物及其制备方法和应用 | |
| El-Sherbiny et al. | Photo-induced green synthesis and antimicrobial efficacy of poly (ɛ-caprolactone)/curcumin/grape leaf extract-silver hybrid nanoparticles | |
| CN106619239A (zh) | 一种含红藻提取物的组合物及其应用 | |
| CN113440423A (zh) | 改性二氧化钛粒子及其制备方法、护肤品 | |
| WO2021174715A1 (zh) | 一种个人护理防晒组合物、制备方法及应用 | |
| Gol’dshleger et al. | Magnesium octa [(4′-benzo-15-crown-5) oxy] phthalocyaninate in water micellar solutions of sodium deoxycholate | |
| CN116236416A (zh) | 一种纳米负载的透明质酸钠及其制备方法和应用 | |
| CN114601743A (zh) | 一种二氢杨梅素脂质体及其制备和应用 | |
| Kim et al. | Pro-NP™ protect against TiO2 nanoparticle-induced phototoxicity in zebrafish model: exploring potential application for skin care | |
| CN110251433A (zh) | 一种香水莲花提取物及其制备方法、包含其的香水莲花水以及莲花保湿舒敏水 | |
| CN1404828A (zh) | 泛硫乙胺磺酸和/或其盐作为自由基清除剂的用途 | |
| Li et al. | Aggregation kinetics of TiO2 nanoparticles in human and artificial sweat solutions: effects of particle properties and sweat constituents | |
| Xiong et al. | Manganese oxide nanoclusters for skin photoprotection | |
| An et al. | Preparation and evaluation of polymer-encapsulated UV filter nanocapsules with miniemulsion polymerization | |
| CN108283621B (zh) | 一种鼻腔纳米制剂糠酸莫米松液晶凝胶纳米粒及其制备方法 | |
| JP6267653B2 (ja) | コロイド銀とデオキシリボ核酸との相乗的組み合わせに基づく皮膚化粧用組成物 | |
| Carlotti et al. | Study on the photodegradation of salicylic acid in different vehicles in the absence and in the presence of TiO2 | |
| CN113101238B (zh) | 一种抗自由基组合物及其制备方法和应用 | |
| CN113069372A (zh) | 一种基于黑色素包覆粒子的防晒组合物及制备方法 | |
| CN112022774A (zh) | 一种皮肤屏障修复组合物及其制备方法与应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20230609 |